Sugi Predict

Sugi Predict / Compounds / SCHEMBL2328812

SCHEMBL2328812

SCHEMBL2328812

CC(C)(C)OC(=O)N1CC(C#N)(CO)C1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 1/20 0.43
▸ NR1H2 P55055 2/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ USP2 O75604 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ JAK1 P23458 2/20 0.36
▸ GPR119 Q8TDV5 2/20 0.36
▸ JAK2 O60674 1/20 0.36
▸ HPGD P15428 1/20 0.35
▸ EPHX2 P34913 1/20 0.35
▸ CTSD P07339 1/20 0.34
▸ CTSL P07711 1/20 0.34
▸ CTSB P07858 1/20 0.34
▸ CTSS P25774 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31451925 0.88 CTSK (0.42) CTSKNR1H2MEN1ALDH1A1MAPT
SCHEMBL2378378 0.87 CTSK (0.43) CTSKNR1H2MEN1ALDH1A1MAPT
SCHEMBL25305211 0.86 CTSK (0.42) CTSKNR1H2MEN1ALDH1A1MAPT
SCHEMBL1707010 0.86 CTSK (0.42) CTSKNR1H2MEN1ALDH1A1MAPT
SCHEMBL31387849 0.86 MEN1 (0.44) CTSKNR1H2MEN1ALDH1A1MAPT
SCHEMBL1476907 0.84 USP2 (0.45) CTSKNR1H2MEN1ALDH1A1MAPT
SCHEMBL2943268 0.82 NR1H2 (0.44) CTSKNR1H2MEN1ALDH1A1MAPT
SCHEMBL27330332 0.82 CTSK (0.39) CTSKNR1H2MEN1ALDH1A1MAPT
SCHEMBL15577439 0.81 CTSK (0.38) CTSKNR1H2MEN1ALDH1A1MAPT
SCHEMBL15577456 0.81 CTSK (0.38) CTSKNR1H2MEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4587424-A1 YAP/TAZ-TEAD ONCOPROTEINS INHIBITORS Bridgene Biosciences, Inc. (US) 2025-07-23 — — EP disclosed
US-20250215029-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. 2025-07-03 — — US disclosed
CN-119894866-A YAP/TAZ-TEAD oncoprotein inhibitors 布里奇恩生物科学公司 2025-04-25 — — CN disclosed
EP-4463459-A1 STAT MODULATORS AND USES THEREOF Recludix Pharma, Inc. (US) 2024-11-20 — — EP disclosed
US-20240174662-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES CILAG AG (CH) 2024-05-30 — — US disclosed
WO-2024059317-A1 YAP/TAZ-TEAD ONCOPROTEINS INHIBITORS BRIDGENE BIOSCIENCES, INC. (US) 2024-03-21 — — WO disclosed
WO-2024059317-A1 YAP/TAZ-TEAD ONCOPROTEINS INHIBITORS BRIDGENE BIOSCIENCES, INC. (US) 2024-03-21 — — WO disclosed
EP-4284802-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES Janssen Biotech, Inc. (US) 2023-12-06 — — EP disclosed
WO-2023133336-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2023-07-13 — — WO disclosed
WO-2023133336-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2023-07-13 — — WO disclosed
US-20190040043-A1 PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2019-02-07 — — US disclosed
US-20190040043-A1 PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2019-02-07 — — US disclosed
EP-2354134-B1 2H-CHROMENE DERIVATIVES AS STIMULATORS OF SPHINGOSINE 1-PHOSPHATE RECEPTOR ASTELLAS PHARMA INC (JP) 2016-02-24 — — EP disclosed
US-20120178735-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF ASTELLAS PHARMA INC. (JP) 2012-07-12 — — US disclosed
US-20120178735-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF ASTELLAS PHARMA INC. (JP) 2012-07-12 — — US disclosed
US-8193378-B2 2H-chromene compound and derivative thereof ASTELLAS PHARMA INC. (JP) 2012-06-05 — — US disclosed
US-8193378-B2 2H-chromene compound and derivative thereof ASTELLAS PHARMA INC. (JP) 2012-06-05 — — US disclosed
US-20110230463-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF ASTELLAS PHARMA INC. (JP) 2011-09-22 — — US disclosed
US-20110230463-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF ASTELLAS PHARMA INC. (JP) 2011-09-22 — — US disclosed
EP-2354134-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF Astellas Pharma Inc. (JP) 2011-08-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230463-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF S1PR1, S1PR2, CCR1 CTSK 889/4885NR1H2 47/4885MEN1 1528/4885
US-20190040043-A1 PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS JAK3, JAK1, JAK2 CTSK 1028/4885NR1H2 4454/4885MEN1 3327/4885
US-20250215029-A1 STAT MODULATORS AND USES THEREOF STAT6, STAT3, STAT5A CTSK 3186/4885NR1H2 926/4885MEN1 2963/4885
US-20240174662-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES SIK2, SIK1, SGK2 CTSK 1178/4885NR1H2 1934/4885MEN1 3588/4885
US-20120178735-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF S1PR1, S1PR2, S1PR4 CTSK 740/4885NR1H2 12/4885MEN1 2001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.